euroscreen

Euroscreen completes enrolment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

on 14/09/2016 10:48
Study evaluating ESN364, a novel, non-hormonal small-molecule drug designed to block Hot Flashes avoiding Hormone Replacement Therapy (HRT), known to increase the incidence of cancer in menopausal women.
Read more

Euroscreen opens US-IND for ESN364 on three Phase II trials

on 19/07/2016 17:16

Euroscreen raises 16 million in Equity Investments

on 02/10/2015 10:52